Navigation Links
Clinical Comparisons Between ADHD Drugs Are Less

Research has shown that there are few clinical comparisons available between the drugs for ADHD. As a result, parents seeking the best individual drug for their children with attention deficit hyperactivity disorder // have little hard evidence to help make that choice.

There are few head-to-head clinical comparisons of many ADHD medications, despite the relatively large variety of drugs prescribed for ADHD and the prevalence of the condition among children and adults, according to a new review from the Oregon Evidence-based Practice Center at the Oregon Health and Science University.

The Oregon Evidence-based Practice Center makes available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes.

The majority of the head-to-head trials identified by the Oregon reviewers compared the widely prescribed ADHD medication Ritalin with other drugs. Most of these comparative trials were short in duration, included only a small number of patients and did not measure the long-term effects of the drugs.

As for safety, the researchers found that short-term, randomized controlled trials do not provide clear evidence that any one stimulant is any more tolerable than another or that non-stimulants are more tolerable than stimulants.

None of the trials compared how well the drugs performed in terms of improving academic performance, quality of life or social skills, the researchers found.

Stimulant medications such as Ritalin and amphetamines are most often prescribed for ADHD, but the Oregon study includes several types of ADHD medications that have never been examined before in a systematic review, including newer stimulants such as modafinil and non-stimulant drugs such as Strattera (atomoxetine), antihypertensive drugs such as guanfacine and older antipsychotic drugs such as clozapine.

Limited evidence suggests that the antihypertensive dr ugs clonidine and guanfacine reduce the severity of facial tics in children with ADHD, but the two drugs are not approved by the Food and Drug Administration for the treatment of ADHD.

Source: Newswise
'"/>




Related medicine news :

1. Clinical trials need to be more frank
2. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
3. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
4. A Novel System For Clinical Banking Of Umbilical Cord Blood
5. Clinical Renal Trails Do Not Have Sufficient Women Participants
6. Clinical Trials of New Drug Febuxostat Show Promise in Gout Treatment
7. Clinical Trials Of New Anti-Cancer Drug To Be Initiated In New Zealand
8. Green Tea Consumption Found To Improve Clinical Outcome In Cancer Patients
9. Cancer Clinical Research in India
10. New Generation Clinical Trials Could Save Time And Money, Improve Patient Care
11. Clinical Impact of Activity and Abdominal Pressure on Pelvic Floor Dysfunction Need to Be Further Analyzed
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/22/2017)... TX (PRWEB) , ... February ... ... Risk Adjustment solution leverages advanced data analytics to accurately understand each Medicare ... proper reimbursement for a given population. This new solution helps transform the ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... Sideline Products ... the company met national TV host Tom Seay and his production crew. Tom ... favorite among equestrians around the world. Saddle Sidekicks will be featured on April ...
(Date:2/22/2017)... ... , ... ANGLESTRONG , the new recovery management app with multiple innovative ... Store and Google Play . Florida-based Sober Network, Inc., the premier provider ... with Angle to build ANGLESTRONG. The new recovery management app is a passion project ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... A product ... people seem to derive a heart-protective benefit from eating soy foods, while others do ... Japanese men who are able to produce equol—a substance made by some types of ...
(Date:2/22/2017)... ... February 22, 2017 , ... Super-Sod will attend the Athens Home ... Athens, Georgia. , A shift from Super-Sod’s simple Athens Home Show booth of 2016, ... booth, grass seed plant manager Chris Roquemore constructed furniture from recycled pallet wood at ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... PORTLAND, Oregon and PUNE, India ... a new report published by Allied Market Research, titled, "Radiology ... User: Global Opportunity Analysis and Industry Forecast, 2014-2022," the radiology ... and is projected to reach $941 million by 2022, growing ... integrated radiology information systems segment held over three-fifths share of ...
(Date:2/22/2017)... On Tuesday, February 21, ... Average, and the S&P 500 edged higher at ... ended Tuesday,s trading session in bullish territories. Taking ... following Medical Instruments & Supplies equities this morning: ... Bard Inc. (NYSE: BCR), Glaukos Corporation (NYSE: GKOS), ...
(Date:2/22/2017)... 2017  Allergan plc (NYSE: AGN), a leading ... Gold sponsor of the Alzheimer,s Foundation of America,s ... tour commemorates AFA,s15 years of educating individuals about ... The tour will include AFA,s free Concepts in ... of the AFA Quilt to Remember. ...
Breaking Medicine Technology: